Viggo Van Tendeloo is Associate Professor at the Vaccine & Infectious Disease Institute of the Faculty of Medicine and Health Sciences of the University of Antwerp. He received his PhD in Biochemistry in 2000 from the University of Antwerp and worked as a postdoc and senior scientist in the Laboratory of Experimental Hematology. In 2007 he became appointed as a full-time research professor in Cellular Immunotherapy at the University of Antwerp. In 2005 he founded together with his mentor Zwi Berneman the Center for Cell Therapy and Regenerative Medicine (CCRG) at the Antwerp University Hospital of which he was the scientific director until 2012. Currently, he heads the Tumor Immunology Group (TIGR) within the Laboratory of Experimental Hematology. He is inventor of a US patent on mRNA electroporation as an efficient transfection method of hematopoietic cells and stem cells. Dr. Van Tendeloo’s research is focused on immunobiology and modulation of human myeloid dendritic cells in order to induce T cell immunity and to enhance their interaction with innate effector cells such as natural killer cells and gd T cells. He is a member of the scientific advisory board of the Belgian Foundation against Cancer and provides expert consultancy to Federal Agency of Medicine and Health Products and to spin-off biotech companies in the field of therapeutic cancer vaccination. He was the principal investigator for a number of completed early-phase clinical trials on personalized cancer and HIV therapeutic vaccines using antigen mRNA‐transfected dendritic cells and is currently involved in the immunomonitoring of tumor-specific immune responses in cancer patients after therapeutic vaccination. To date, he has authored more than 100 peer-reviewed papers and has an h-index of 29.
Top 5 of most significant papers during career:
Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Van Tendeloo VF, Berneman ZN. Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacol Rev. 2015;67(4):731-53. (SCI IF 18.551)
Anguille S, Smits E, Lion E, Van Tendeloo VFI, Berneman ZN. The clinical use of dendritic cells for cancer therapy: paradoxes, facts and emerging paradigms. Lancet Oncology 2014 Jun;15(7):e257-e267. (SCI IF 24.725)
Van Tendeloo VFI, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, Gadisseur AP, Vrelust I, Jorens PG, Goossens H, de Vries IJ, Price DA, Oji Y, Oka Y, Sugiyama H, Berneman ZN. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Sciences of the USA 2010; 107: 13824-13829. (SCI IF: 9.432)
Van Gulck E*, Vlieghe E*, Vekemans M*, Van Tendeloo VF*, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012; 26: F1-F12. (SCI IF: 6.348)
*equally contributed as first author
Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia (review). Leukemia 2012 Oct;26(10):2186-96. (SCI IF 9.561)